Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Proof-of-Concept Study of VK2809 for the Treatment of Glycogen Storage Disease Type Ia (GSD Ia)

Trial Profile

A Proof-of-Concept Study of VK2809 for the Treatment of Glycogen Storage Disease Type Ia (GSD Ia)

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 28 Aug 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VK 2809 (Primary)
  • Indications Glycogen storage disease type I
  • Focus Adverse reactions; Proof of concept
  • Sponsors Viking Therapeutics
  • Most Recent Events

    • 28 Aug 2018 I have assumed 1 Sep 2018 as planned start date (third quarter-July passed and Aug almost passed).Also, I have assumed trial focus as AR based on trial phase (I).Please update it according to registry source primary endpoints.
    • 09 Aug 2018 According to a Viking Therapeutics media release, the company plans to begin dosing patients in this trial in the third quarter of 2018.
    • 17 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top